Digital Therapeutics Market (2026 - 2033)

Digital Therapeutics Market Summary

The global digital therapeutics market size was valued at USD 9.5 billion in 2025 and is projected to grow from USD 12.0 billion in 2026 to USD 75.2 billion by 2033, at a CAGR of 30.0% from 2026 to 2033. North America dominated the market with a revenue share of 39.8% in 2025. Market growth is being supported by the rising prevalence of chronic diseases, increasing smartphone and internet penetration, growing demand for remote and personalized healthcare, and efforts to improve treatment accessibility and cost efficiency.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The global digital therapeutics (DTx) market is rapidly expanding as healthcare systems increasingly shift toward patient-centered, technology-enabled models of care. Digital therapeutics are software-based interventions designed to prevent, manage, or treat medical conditions through clinically evaluated methods and measurable health outcomes. DTx aims to deliver specific therapeutic benefits and can be integrated into treatment pathways alongside conventional medical care. Their ability to provide personalized interventions, behavioral support, continuous monitoring, and data-driven feedback is enhancing their relevance across a range of chronic and lifestyle-related conditions, including diabetes, obesity, cardiovascular disease, respiratory conditions, central nervous system disorders, and smoking cessation.

To learn more about this report, Download Free Sample Report

In the U.S., the Centers for Medicare & Medicaid Services (CMS) introduced three new remote therapeutic monitoring codes effective January 2026. These codes specifically address therapy adherence, therapy response, and digital therapeutic interventions. In Germany, a formal regulatory and reimbursement pathway has been established through the Digital Health Applications (DiGA) framework, with the Federal Institute for Drugs and Medical Devices (BfArM) maintaining a directory of assessed digital health applications and their associated prescribing information. The commercialization environment is becoming more supportive as reimbursement and regulatory frameworks are evolving. These developments are enhancing the integration of digital therapeutics into conventional healthcare delivery and creating clearer pathways for providers, patients, and technology developers.

Moreover, the digital therapeutics industry is moving toward more sophisticated digital interventions that incorporate artificial intelligence, connected devices, behavioral analytics, and real-time health data. In July 2026, the U.S. Food and Drug Administration (FDA) selected the first participant for its TEMPO pilot program for digital health devices, developed in collaboration with the CMS Innovation Center. This initiative aims to generate real-world evidence and improve access to technology-enabled care for chronic disease management. As healthcare providers and payers increasingly emphasize value-based care, digital therapeutics are evolving from standalone software products to integrated components of broader digital healthcare ecosystems. 

The expansion of mobile connectivity, smartphone adoption, and internet access is broadening the user base for digital therapeutics. Greater access to connected devices allows patients to receive software-based interventions, monitor treatment progress, and engage with healthcare providers outside traditional clinical settings. This is particularly relevant to chronic disease management, where continuous patient engagement and behavioral support are important components of care. As consumers become more familiar with mobile health applications, their acceptance of technology-enabled healthcare is also increasing, creating a stronger foundation for the adoption of clinically validated digital therapeutics.

To learn more about this report, Download Free Sample Report

The rising prevalence of chronic diseases is driving sustained demand for scalable, accessible disease management solutions. Conditions such as diabetes, cardiovascular disease, obesity, respiratory diseases, and mental health disorders often require continuous monitoring, behavioral modification, and long-term patient engagement-areas where digital therapeutics can complement conventional treatment approaches. According to the CDC, approximately three in four U.S. adults had at least one chronic condition in 2026, while more than half had two or more. The increasing burden of multimorbidity is consequently strengthening the need for personalized interventions that support treatment adherence, symptom management, and ongoing care beyond healthcare facilities.

Digital therapeutics are also becoming increasingly integrated into broader remote and value-based healthcare models. Their ability to deliver standardized interventions, collect patient-generated data, monitor adherence, and provide personalized feedback allows them to support continuous disease management without relying solely on frequent in-person consultations. The expansion of remote therapeutic monitoring is particularly relevant, as it provides healthcare professionals with mechanisms to incorporate technology-enabled monitoring and treatment management into established care pathways. As providers and payers place greater emphasis on measurable outcomes, adherence, and efficient resource utilization, the role of clinically validated digital therapeutics is expected to expand.

Investment activity within digital health continues to influence product development, commercialization, and technological innovation across the digital therapeutics ecosystem. Funding is increasingly directed toward companies with established products, clinical evidence, healthcare partnerships, and defined reimbursement or commercialization pathways. This is encouraging developers to place greater emphasis on demonstrating measurable clinical and economic outcomes rather than on consumer engagement alone. At the same time, advances in artificial intelligence, behavioral analytics, connected devices, and personalized digital interventions are expanding the capabilities of digital therapeutic platforms and supporting their use across chronic disease management, mental health, neurological disorders, and other therapeutic areas.

To learn more about this report, Download Free Sample Report

The regulatory landscape for digital therapeutics is becoming favorable, with increasing recognition of their potential benefits. This is encouraging more investment and development in digital therapeutics (DTx) and making it easier for companies to bring their products to market. There is a growing movement towards value-based care, which emphasizes the quality and effectiveness of care over the quantity of services provided. Digital therapeutics products are suited to value-based care models, as they can be shown to improve patient outcomes and reduce healthcare costs. Recent regulatory changes, such as the FDA's establishment of the Digital Health Center of Excellenceand the introduction of new reimbursement codes for remote therapeutic monitoring (RTM), are further supporting the adoption of DTx. Remote therapeutic monitoring codes (98975, 98976, 98977, 98980, and 98981) specify initial setup, education, and device provision, plus two codes for clinician time spent on RTM treatment. These codes support clinical staff in performing RTM remotely, aligning with existing remote and chronic care policies. 

Market Dynamics

The growth of the digital therapeutics market is largely driven by the cost-effectiveness of digital health technologies for both providers and patients, as well as increasing smartphone penetration in developed and developing countries alike. There is a rising demand for patient-centered care and integrated healthcare systems, which is also expected to contribute to market growth. Additionally, supportive reimbursement policies and the rising incidence of chronic diseases are likely to drive market expansion further.

Market Concentration & Characteristics

The digital therapeutics market is characterized by continued product innovation, expansion across therapeutic areas, and increasing integration of artificial intelligence (AI), connected devices, and behavioral analytics. Developers are increasingly focusing on prescription digital therapeutics that can complement conventional pharmacological treatments and deliver measurable clinical outcomes. Product development is expanding beyond established areas such as diabetes and mental health toward migraine, schizophrenia, obesity, neurological disorders, and cardiometabolic conditions. In April 2025, Click Therapeutics announced FDA marketing authorization for CT-132 to prevent episodic migraine, expanding the use of prescription digital therapeutics in neurology. In April 2026, Click Therapeutics and Boehringer Ingelheim announced a USD 50 million Series D strategic investment and additional funding to support the commercialization of CT-155, an investigational prescription digital therapeutic for negative symptoms of schizophrenia, subject to FDA clearance.

AI is becoming an increasingly important component of digital therapeutics development, supporting personalized interventions, patient engagement, and data-driven treatment approaches. Developers are combining AI and machine learning with behavioral data, wearable devices, and patient-generated health information to adapt digital interventions to individual patient needs. The involvement of pharmaceutical companies is also strengthening the commercialization ecosystem by combining clinical development expertise, therapeutic-area knowledge, and digital technologies. In November 2023, AstraZeneca launched Evinova as a health-tech business focused on digital health solutions, including remote patient monitoring and digital therapeutics, with capabilities spanning data science, AI, behavioral science, and digital product development.

To learn more about this report, Download Free Sample Report

Regulatory and reimbursement developments continue to influence the commercialization of digital therapeutics across major markets. In the U.S., digital therapeutic developers must address requirements related to medical-device regulation, clinical evidence, patient safety, cybersecurity, and data privacy, while reimbursement remains an important consideration for broader adoption. In January 2026, CMS introduced new remote therapeutic monitoring codes that reference therapy adherence, therapy response, and digital therapeutic intervention, providing additional mechanisms for incorporating eligible technology-enabled services into clinical care. Germany's DiGA framework also provides an established pathway for certain digital health applications to undergo assessment and gain access to statutory health insurance reimbursement. These developments are encouraging companies to place greater emphasis on clinical validation, interoperability, patient outcomes, and evidence of value to the healthcare system.

Strategic partnerships, investments, and portfolio expansion are increasingly shaping the competitive landscape of the digital therapeutics industry. Pharmaceutical companies, technology providers, healthcare organizations, and specialized DTx developers are collaborating to combine therapeutic expertise with software development and digital engagement capabilities. In January 2026, Click Therapeutics and Ultrahuman announced a partnership to develop a biomarker-driven migraine management tool based on Click's FDA-authorized technology, illustrating the growing convergence between prescription digital therapeutics and wearable health technologies. In 2024, Click acquired assets from Better Therapeutics, expanding its portfolio to include cardiometabolic applications, such as treatments for type 2 diabetes. These collaborations and portfolio expansions are enhancing the therapeutic capabilities of digital therapeutics (DTx) platforms, offering developers more avenues for commercialization and improving patient access.

Analyst Perspective

The digital therapeutics market is evolving as healthcare providers and patients increasingly adopt software-based interventions for disease management and behavioral care. The market is shifting toward clinically validated solutions for chronic diseases, mental health, and targeted indications, supported by growing emphasis on evidence-based care. Developers are strengthening clinical validation, regulatory compliance, and integration with healthcare workflows, while AI, connected devices, and remote patient monitoring enable more personalized interventions. Reimbursement pathways, physician adoption, patient engagement, and measurable clinical outcomes remain key commercialization factors. Future growth will depend on integrating digital therapeutics into routine care, generating stronger clinical evidence, and establishing sustainable business models that support adoption by healthcare systems and payers.

Application Insights

The diabetes segment dominated the digital therapeutics market, accounting for a revenue share of 30.1% in 2025, and is expected to register the fastest CAGR of 31.6% during the forecast period. Growth is supported by the substantial and increasing burden of diabetes worldwide, which creates sustained demand for solutions that support glucose management, medication adherence, lifestyle modification, and behavioral change. The U.S. CDC estimated that 40.1 million people in the country had diagnosed or undiagnosed diabetes in 2023, while 115.2 million adults had prediabetes. The growing availability of connected glucose monitoring, digital coaching, and clinically validated diabetes management applications is further expanding the role of digital therapeutics in chronic disease care.

The integration of digital therapeutics with continuous glucose monitoring, wearable devices, remote monitoring, and AI-enabled analytics is creating additional opportunities for the diabetes application segment. The American Diabetes Association's 2026 Standards of Care recommend considering technologies such as CGM, insulin pumps, and diabetes apps, as well as online or virtual coaching, to improve glycemic outcomes in people with diabetes or prediabetes. As DTx platforms increasingly combine patient-generated data with personalized feedback and behavioral interventions, their applications are expanding from basic disease management to continuous, data-driven care.

The obesity segment accounted for the second-largest revenue share in 2025, supported by the growing prevalence of overweight and obesity and increasing demand for scalable weight-management interventions. Digital therapeutics can support behavioral modification through personalized nutrition guidance, physical activity tracking, coaching, and adherence support, making them increasingly relevant as complementary tools within broader obesity management programs. Cardiovascular disease and smoking cessation are also expected to witness significant growth as healthcare providers increasingly adopt digital interventions for behavioral risk modification, disease prevention, and long-term patient engagement.

End Use Insights

The patients segment dominated the digital therapeutics industry, accounting for a revenue share of 35.0% in 2025, and is expected to grow at the fastest CAGR during the forecast period. Growth is supported by increasing patient adoption of personalized, evidence-based digital interventions for chronic disease management, behavioral modification, medication adherence, and disease monitoring. Digital therapeutics can extend care beyond conventional clinical settings by enabling patients to access therapeutic programs remotely and share health information with providers. The increasing integration of digital therapeutics with connected devices, remote monitoring, and digital coaching is further strengthening patient engagement and supporting continuous management of chronic conditions. In February 2026, the CDC highlighted telehealth as an efficient and scalable approach to delivering diabetes self-management education and support, particularly for underserved populations facing transportation and provider access barriers.

To learn more about this report, Download Free Sample Report

The employers segment is expected to grow at the fastest CAGR of 30.8% during the forecast period. Growing interest in digital therapeutics is driving growth within employer-sponsored health and wellness programs. Employers are increasingly adopting digital interventions to provide their employees with convenient and scalable support for behavioral health, chronic conditions, and lifestyle-related health needs. Digital therapeutics can be accessed remotely and integrated into existing employee benefits platforms, thereby expanding access and reducing logistical barriers. A growing emphasis on employee well-being, healthcare cost management, and preventive care is encouraging employers to further explore technology-enabled interventions. Moreover, the integration of virtual care, digital health platforms, and connected devices is enhancing the potential role of digital therapeutics in workplace healthcare programs. As employers focus more on measurable health outcomes and employee engagement, the demand for clinically supported digital interventions is expected to grow.

Regional Insights

North America dominated the digital therapeutics market, accounting for the largest revenue share of 39.8% in 2025. The regional market is expected to maintain strong growth through the forecast period, supported by the increasing adoption of digital health technologies, expanding reimbursement opportunities, and growing emphasis on technology-enabled chronic disease management. Rising smartphone penetration, widespread access to high-speed connectivity, increasing healthcare costs, and the growing burden of chronic diseases are supporting demand for digital therapeutics across the region. In addition, the integration of digital therapeutics with remote monitoring, connected devices, and personalized care models is strengthening their role in extending healthcare delivery beyond traditional clinical settings. In January 2026, CMS introduced new remote therapeutic monitoring (RTM) codes covering therapy adherence, therapy response, and digital therapeutic interventions, further supporting the integration of technology-enabled therapies into reimbursed care pathways.

To learn more about this report, Download Free Sample Report

The U.S. digital therapeutics marketaccounted for 82.6% of North America in 2025, driven by its robust digital health ecosystem and regulatory support for software-based chronic care interventions. Key developments include the FDA's TEMPO pilot, launched in July 2026 to promote digital health technologies in chronic disease management, and a USD 50 million investment in April 2026 by Click Therapeutics and Boehringer Ingelheim for CT-155, a digital therapeutic for schizophrenia. These trends highlight the growing integration of digital therapeutics, clinical evidence, and value-based care in the U.S. healthcare system.

Europe Digital Therapeutics Market Trends

Europe’s digital therapeutics industry is expected to gain momentum over the forecast period, supported by increasing adoption of digital health technologies, established healthcare systems, and growing emphasis on evidence-based, technology-enabled care. Germany, the UK, France, Italy, and Spain represent important markets across the region, with digital therapeutics increasingly being integrated into chronic disease management, mental healthcare, and remote care pathways. The implementation of the European Health Data Space (EHDS), which entered into force in March 2025, is expected to support further interoperability and secure exchange of electronic health data across European healthcare systems. The framework is intended to facilitate evidence-based care, personalized treatment, and innovation in digital health while creating a more harmonized environment for health technology adoption.

The UK digital therapeutics market is set to grow as the NHS increases its adoption of digitally enabled care, with a focus on clinical evidence and patient outcomes. NHS England has established criteria for these therapies, emphasizing clinical effectiveness and safety for routine use in NHS Talking Therapies. The NHS Medium Term Planning Framework for 2026/27-2028/29 also encourages the integration of digital therapeutics for supportive care and clinical delivery, enhancing the role of validated digital interventions within the UK healthcare system.

Asia Pacific Digital Therapeutics Market Trends

The Asia Pacific digital therapeutics industry is expected to grow at the fastest CAGR of 32.1% over the forecast period, supported by expanding healthcare digitization, rising smartphone and internet penetration, a growing burden of chronic diseases, and increasing government investment in digital health infrastructure. The region's large and aging population, combined with disparities in healthcare access between urban and remote areas, is driving demand for technology-enabled approaches to chronic disease management and continuous patient engagement. Japan, China, South Korea, Australia, and other developed Asia Pacific markets are advancing digital healthcare infrastructure, while emerging economies are expanding access to mobile-based healthcare services. The increasing integration of software, connected devices, remote monitoring, and artificial intelligence into healthcare delivery is expected further to support the adoption of digital therapeutics across the region. 

Latin America Digital Therapeutics Market Trends

The Latin America digital therapeutics industry is poised for growth as healthcare systems embrace digital transformation and technology-enabled care. Factors such as increased internet and smartphone use, heightened awareness of digital healthcare, a rising burden of chronic diseases, and the need for better healthcare access are driving this trend. Governments are enhancing digital health infrastructure and telehealth capabilities. Notably, in August 2026, Brazil's National Council of Health approved a policy to integrate clinical data and improve healthcare efficiency and accessibility. These initiatives are expected to bolster the infrastructure needed for wider adoption of digital therapeutics and remote care in the region.

Middle East & Africa Digital Therapeutics Market Trends

The Middle East and Africa (MEA) digital therapeutics industry is poised for growth as healthcare systems undergo digital transformation. Factors such as rising smartphone usage, increased access to telehealth, and a growing burden of chronic disease are driving this trend. Government-led initiatives to enhance digital health infrastructure further support the adoption of technology-enabled care. In February 2026, the WHO African Region began consultations for the Global Strategy on Digital Health 2028-2033, emphasizing interoperability, sustainable financing, workforce capacity, and equitable access. These efforts will facilitate the integration of digital therapeutics with remote monitoring and chronic disease management in MEA.

Key Digital Therapeutics Company Insights

The global digital therapeutics market is characterized by active competition among specialized digital therapeutics developers, pharmaceutical companies, and digital health technology providers. Companies are pursuing strategic partnerships, collaborations, licensing agreements, and investments to expand therapeutic pipelines, strengthen clinical and commercialization capabilities, and integrate digital therapeutics with broader healthcare platforms. These developments highlight the increasing integration of digital therapeutics with pharmaceutical development, wearable technologies, and personalized digital healthcare.

Key Digital Therapeutics Companies

The following key companies have been profiled for this study on the digital therapeutics market.

• 2Morrow, Inc.

• Big Health

• Canary Health

• DarioHealth Corp.

• GAIA AG

• Hygieia, Inc.

• Noom, Inc.

• Omada Health, Inc.

• ResMed

• Teladoc Health

• Virtual Therapeutics

• Welldoc, Inc.

Recent Developments

• In July 2026, XRHealth acquired Swing Therapeutics, adding FDA-authorized digital therapeutics for fibromyalgia and chronic pain to its platform. The acquisition expands XRHealth’s portfolio beyond immersive technologies into mobile digital therapeutics, wearables, and virtual care.

• In April 2026, Boehringer Ingelheim and Click Therapeutics revised their strategic agreement for CT-155, an investigational prescription digital therapeutic for schizophrenia. Click assumed full commercial and marketing authorization rights, while Boehringer committed USD 50 million through a Series D investment and additional funding to support commercialization.

• In January 2026, Ultrahuman and Click Therapeutics partnered to develop Migraine PowerPlug, combining Ultrahuman’s biomarker analytics with technology underlying Click’s FDA-authorized migraine digital therapeutic. The tool is designed to provide personalized migraine insights and guided behavioral interventions through Ultrahuman’s platform.

• In March 2025, ATA Action acquired the Digital Therapeutics Alliance (DTA) to create a unified platform for policy and advocacy supporting digital therapeutics and other technology-enabled healthcare solutions.

Global Digital Therapeutics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global digital therapeutics market report based on application, end use, and region:

To learn more about this report, Download Free Sample Report

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Diabetes

  • Obesity

  • CVD

  • Respiratory Diseases

  • Smoking Cessation

  • CNS Diseases

  • Others

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Patients

  • Providers

  • Payers

  • Employers

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

    • Rest of Europe

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Thailand

    • Rest of Asia Pacific

  • Latin America

    • Brazil

    • Argentina

    • Rest of Latin America

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

    • Rest of Middle East & Africa

Research Methodology

The digital therapeutics market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each digital therapeutics segment quantified using the revenue-capture definitions in the table below.

Estimation Model

Our research methodology entails an ideal mixture of primary and secondary initiatives. The key steps involved in the process are listed below:

• Information procurement

  • The stage involves the procurement of market data or related information via different sources & methodologies.

• Information analysis

  • This step involves the analysis & mapping of all the information procured from the previous step. It also encompasses the analysis of data discrepancies observed across various data sources.

• Market formulation

  • The final step entails the placement of data points at appropriate market spaces in an attempt to deduce viable conclusions. Analyst perspective & subject matter expert-based heuristic form of market sizing also play an integral role in this step.

• Validation & publishing

  • Validation is the most important step in the process. Validation & revalidation through an intricately designed process help us finalize data points for the final calculations.

The movement between steps 1 and 2 is bidirectional. The process follows a to & for from both ends. This is an integral data filtration technique used by GVR. The validation & market formulation steps are also reversible. They are running in parallel to ensure data accuracy and process flexibility.

The process of market sizing & data point identification runs throughout the report schedule. The process moves from steps 1&2 to steps 3&4 while keeping the steps 1&2 and 3&4 reversible. The cycle of market sizing & variable identification also repeats until every data point is duly validated and fit for publication.

Market-Specific Research Models

• Multi-Lens Modeling Framework (Model 1)

The study incorporates three independent yet interlinked analytical lenses:

Model 1: Bottom-Up Platform Analysis (MAU-Driven Model)

• Aggregated data across key digital health companies.

• Key inputs:

  • Monthly Active Users (MAU)

  • Paying users/subscribers

  • Visit frequency

  • Conversion rates

• Revenue derived using:

  • Consultation monetization

  • Subscription-based services

  • Platform-driven healthcare transactions

Model 2: Healthcare Utilization Model (Demand-Side Validation)

• Estimated total healthcare interactions globally and applied:

  • Digital health penetration rates

  • Average revenue per interaction

• Incorporated:

  • Outpatient visit volumes

  • Chronic disease burden

  • Virtual care adoption trends

Model 3: Infrastructure & Ecosystem Layer (Supply-Side Model)

• Captures non-consultation revenue streams:

  • Remote Patient Monitoring (RPM)

  • Digital Health software platforms

  • Connected medical devices

• Inputs include:

  • RPM patient population

  • Device penetration

  • SaaS pricing benchmarks

  • Replacement cycles

• Model 2: Commodity Flow Analysis

Commodity flow analysis was employed to track the movement of digital therapeutics through the value chain, from technology providers to end users. This analysis provided insights into demand generation points, intermediary roles, and ultimate consumption patterns.

Delivered Customizations

This report has been delivered with the following In-depth customizations